Systematic review: Sprue-like enteropathy associated with olmesartan

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 1, 2014, Pages 16-23

  Ianiro, G ^a   Bibbo S ^a   Montalto, M ^a   Ricci, R ^a   Gasbarrini, A ^a   Cammarota, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OLMESARTAN;

CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DATA ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOSCOPY; ENTEROPATHY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INTESTINE VILLUS ATROPHY; NORMOCHROMIC NORMOCYTIC ANEMIA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; REVIEW; SPRUE LIKE ENTEROPATHY; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATROPHY; CELIAC DISEASE; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; DUODENUM; HUMANS; IMIDAZOLES; MICROVILLI; TETRAZOLES; WEIGHT LOSS;

EID: 84902084334     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12780     Document Type: Review

References (28)

1. Ludvigsson JF, Brandt L, Montgomery SM, et al,. Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC Gastroenterol 2009; 9: 19.
2. De Gaetani M, Tennyson CA, Lebwohl B, et al,. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol 2013; 108: 647-53.
3. Ziegler TR, Fernández-Estívariz C, Gu LH, et al,. Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology 2003; 124: 1950-7.
4. Kamar N, Faure P, Dupuis E, et al,. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int 2004; 17: 463-7.
5. Weclawiak H, Ould-Mohamed A, Bournet B, et al,. Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation. Am J Transplant 2011; 11: 575-82.
6. Boscá MM, Añõn R, Mayordomo E, et al,. Methotrexate induced sprue-like syndrome. World J Gastroenterol 2008; 14: 7009-11.
7. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, US Department of Health and Human Services; 2004. NIH Publication No. 04-5230.
8. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al,. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732-8.
9. Moher D, Liberati A, Tetzlaff J, et al,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-9.
10. de Fonseka A, Tuskey A, Moskaluk C,. A case of olmesartan induced enteropathy. Inflamm Bowel Dis 2012; 18: S17.
11. Talbot GH,. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc 2012; 87: 1231-2.
12. Dreifuss SE, Tomizawa Y, Farber NJ, et al,. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med 2013; 2013: 618071.
13. Nielsen JA, Steephen A, Lewin M,. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol 2013; 19: 6928-30.
14. Nunge D, Eoche M, Fumery M, et al,. Severe enteropathy with villous atrophy olmesartan medoxomil-associated. Therapie 2013; 68: 419-21.
15. Stanich PP, Yearsley M, Meyer MM,. Olmesartan-associated sprue-like enteropathy. J Clin Gastroenterol 2013; 47: 894-5.
16. Gaur V, Albeldawi M, Weber L,. Chronic diarrhea and weight loss. Gastroenterology 2014; 146: 591.
17. Tran TH, Li H,. Olmesartan and drug-induced enteropathy. P T 2014; 39: 47-50.
18. Theophile H, David XR, Miremont-Salame G, et al,. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis 2014; 46: 465-9.
19. Oberhuber G, Granditsch G, Vogelsang H,. The histopathology of celiac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999; 11: 1185-94.
20. DiGiacomo D, Santonicola A, Zingone F, et al,. Human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases. World J Gastroenterol 2013; 19: 2507-13.
21. Cammarota G, Pirozzi GA, Martino A, et al,. Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. Gastrointest Endosc 2004; 60: 223-8.
22. Cammarota G, Ianiro G, Sparano L, et al,. Image-enhanced endoscopy with I-Scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci 2013; 58: 1287-92.
23. Green PH, Cellier C,. Celiac disease. N Engl J Med 2007; 357: 1731-43.
24. Fändriks L,. The angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst 2010; 11: 43-8.
25. Mavromoustakos T, Agelis G, Durdagi S,. AT1 antagonists: a patent review (2008-2012). Expert Opin Ther Pat 2013; 23: 1483-94.
26. Sun L, Wang W, Xiao W, et al,. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA-6 and the Bax pathway. Biochem Biophys Res Commun 2012; 424: 663-8.
27. de Godoy MA, Rattan S,. Translocation of AT1- and AT2-receptors by higher concentrations of angiotensin II in the smooth muscle cells of rat internal anal sphincter. J Pharmacol Exp Ther 2006; 319: 1088-95.
28. Naranjo CA, Busto U, Sellers EM, et al,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.